206:@0.017061:0.038809:0.056572:0.038809:0.056572:0.019212:0.017061:0.019212:0.013170:0.013170:0.013170
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
Journal  of  Geriatric  Oncology.:@0.131885:0.078073:0.406007:0.078073:0.406007:0.064068:0.131885:0.064068:0.008039:0.010998:0.010194:0.004943:0.010228:0.011477:0.003216:0.004738:0.009604:0.010998:0.005166:0.004738:0.009604:0.014710:0.010913:0.004943:0.003216:0.011477:0.005593:0.004943:0.003216:0.010861:0.004738:0.009602:0.014658:0.010228:0.010861:0.010998:0.003216:0.010998:0.011306:0.008963:0.004738
  2012;3: :@0.405801:0.078073:0.480503:0.078073:0.480503:0.064068:0.405801:0.064068:0.004738:0.009604:0.009271:0.009271:0.009271:0.009271:0.004533:0.009271:0.004736:0.004738
41-48.:@0.131885:0.092208:0.179179:0.092208:0.179179:0.078203:0.131885:0.078203:0.009271:0.009271:0.005473:0.009271:0.009271:0.004738
36.:@0.084848:0.106343:0.108538:0.106343:0.108538:0.092337:0.084848:0.092337:0.009476:0.009476:0.004738
  Fitzpatrick  FA,  Wheeler  R.  The  immunop-:@0.131885:0.106343:0.475755:0.106343:0.475755:0.092337:0.131885:0.092337:0.004738:-0.004738:0.008296:0.003421:0.005798:0.007269:0.011665:0.011682:0.005798:0.005148:0.003421:0.011067:0.008586:0.004738:0.003147:0.007266:0.012657:0.004738:0.004738:0.003149:0.016420:0.010434:0.011118:0.011118:0.003421:0.011118:0.005148:0.004738:0.003147:0.010382:0.004738:0.004738:0.003152:0.007286:0.010434:0.011118:0.004738:0.003147:0.003421:0.016044:0.016044:0.010399:0.010434:0.011203:0.011665:0.005679
harmacology of paclitaxel (Taxol ), doc-:@0.131885:0.120477:0.475756:0.120487:0.475756:0.106481:0.131885:0.106472:0.010434:0.011682:0.005620:0.016044:0.011682:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.006842:0.011203:0.005371:0.006842:0.011665:0.011682:0.011067:0.003421:0.003421:0.005798:0.011682:0.008210:0.011118:0.003421:0.006857:0.006312:0.006400:0.011682:0.008210:0.011203:0.003421:0.007450:0.006312:0.004738:0.006842:0.011716:0.011203:0.011067:0.829585
®:@0.410750:0.115492:0.418199:0.115492:0.418199:0.107327:0.410750:0.107327:0.007449
etaxel (Taxotere ), and related agents. :@0.131890:0.134621:0.480517:0.134624:0.480517:0.120619:0.131890:0.120616:0.011118:0.005798:0.011682:0.008210:0.011118:0.003421:0.010365:0.006312:0.006400:0.011682:0.008210:0.011203:0.005798:0.011118:0.005071:0.011118:0.007437:0.006312:0.004738:0.010365:0.011682:0.010434:0.011716:0.010365:0.005078:0.011118:0.003421:0.011682:0.005798:0.011118:0.011716:0.010365:0.011682:0.011511:0.011118:0.010434:0.005798:0.006636:0.004738:0.803319
®:@0.270503:0.129630:0.277952:0.129630:0.277952:0.121465:0.270503:0.121465:0.007449
International Immunopharmacology.:@0.131881:0.148759:0.475780:0.148759:0.475780:0.134754:0.131881:0.134754:0.004892:0.011460:0.006825:0.012144:0.006175:0.011460:0.012709:0.006825:0.004447:0.012230:0.011460:0.012709:0.004447:0.012743:0.004892:0.017070:0.017070:0.011426:0.011460:0.012230:0.012691:0.011460:0.012709:0.006175:0.017070:0.012709:0.012093:0.012230:0.004447:0.012230:0.011508:0.009170:0.004738
 :@0.475747:0.148759:0.480485:0.148759:0.480485:0.134754:0.475747:0.134754:0.004738
2003;3:1699-1714. :@0.131881:0.162894:0.279697:0.162894:0.279697:0.148888:0.131881:0.148888:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738
37.:@0.084844:0.177028:0.108534:0.177028:0.108534:0.163023:0.084844:0.163023:0.009476:0.009476:0.004738
  Sanofi-aventis.  Jevtana  (cabazitaxel).:@0.131881:0.177028:0.475744:0.177038:0.475744:0.163032:0.131881:0.163023:0.004738:-0.004738:0.008518:0.011682:0.010434:0.011203:0.004165:0.004165:0.005679:0.011682:0.009476:0.011118:0.010434:0.005798:0.003421:0.006636:0.004738:0.004738:0.012486:0.008244:0.011118:0.009476:0.005798:0.011682:0.010434:0.011682:0.007455:0.017224:0.006312:0.011067:0.011682:0.011665:0.011682:0.007269:0.003421:0.005798:0.011682:0.008210:0.011118:0.003421:0.006312:0.746400
®:@0.336694:0.172043:0.344143:0.172043:0.344143:0.163878:0.336694:0.163878:0.007449
(Sanofi Aventis, published online, 2012) :@0.131878:0.191172:0.454518:0.191172:0.454518:0.177167:0.131878:0.177167:0.006312:0.008518:0.011682:0.010434:0.011203:0.004165:0.004165:0.004738:0.011392:0.009476:0.011118:0.010434:0.005798:0.003421:0.006636:0.004738:0.004738:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
38. :@0.084841:0.205307:0.113269:0.205307:0.113269:0.191302:0.084841:0.191302:0.009476:0.009476:0.004738:0.004738
  Thomas ES,:@0.131878:0.205307:0.220912:0.205307:0.220912:0.191302:0.131878:0.191302:0.004738:-0.004738:0.007286:0.010434:0.011203:0.016044:0.011682:0.006636:0.003323:0.009168:0.008518:0.004738
 et al.:@0.220912:0.205307:0.264329:0.205307:0.264329:0.191302:0.220912:0.191302:0.003335:0.011118:0.005798:0.003325:0.011682:0.003421:0.004738
 Ixabepilone plus capecit-:@0.264329:0.205307:0.475756:0.205307:0.475756:0.191302:0.264329:0.191302:0.003335:0.003866:0.008210:0.011682:0.011665:0.011118:0.011665:0.003421:0.003421:0.011203:0.010434:0.011118:0.003335:0.011665:0.003421:0.010399:0.006636:0.003335:0.011067:0.011682:0.011665:0.011118:0.011067:0.003421:0.005798:0.005679
abine for metastatic breast cancer pro-:@0.131878:0.219441:0.475744:0.219441:0.475744:0.205436:0.131878:0.205436:0.011682:0.011665:0.003421:0.010434:0.011118:0.007731:0.005371:0.011203:0.005148:0.007731:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.007731:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.007731:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.007731:0.011665:0.005080:0.011203:0.005679
gressing after anthracycline and taxane :@0.131878:0.233576:0.480494:0.233576:0.480494:0.219571:0.131878:0.219571:0.011511:0.005075:0.011118:0.006636:0.006636:0.003421:0.010434:0.011511:0.007697:0.011682:0.005371:0.005798:0.011118:0.005148:0.007697:0.011682:0.010434:0.005798:0.010434:0.005148:0.011682:0.011067:0.009168:0.011067:0.003421:0.003421:0.010434:0.011118:0.007697:0.011682:0.010434:0.011716:0.007697:0.005798:0.011682:0.008210:0.011682:0.010434:0.011118:0.004738
treatment. :@0.131878:0.247711:0.224220:0.247711:0.224220:0.233705:0.131878:0.233705:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738:0.004738
Journal of Clinical Oncology.:@0.227167:0.247711:0.475732:0.247711:0.475732:0.233705:0.227167:0.233705:0.008244:0.011203:0.010399:0.005148:0.010422:0.011682:0.003421:0.007697:0.011203:0.005371:0.007697:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.007697:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738
 :@0.475732:0.247711:0.480470:0.247711:0.480470:0.233705:0.475732:0.233705:0.004738
2007;25:5210-5217.:@0.131878:0.261845:0.284432:0.261845:0.284432:0.247840:0.131878:0.247840:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
39.:@0.084841:0.275980:0.108531:0.275980:0.108531:0.261975:0.084841:0.261975:0.009476:0.009476:0.004738
  Argyriou AA,  Kalofonos  HP. Recent  ad-:@0.131878:0.275980:0.475743:0.275980:0.475743:0.261975:0.131878:0.261975:0.004738:-0.004738:0.012657:0.005148:0.011511:0.009168:0.005148:0.003421:0.011203:0.010399:0.009989:0.012657:0.012657:0.004738:0.004738:0.005234:0.010109:0.011682:0.003421:0.011203:0.005371:0.011203:0.010434:0.011203:0.006636:0.004738:0.005241:0.011682:0.008571:0.004738:0.009989:0.010382:0.011118:0.011067:0.011118:0.010434:0.005798:0.004738:0.005241:0.011682:0.011716:0.005679
vances relating to the clinical application :@0.131878:0.290115:0.480477:0.290115:0.480477:0.276109:0.131878:0.276109:0.009476:0.011682:0.010434:0.011067:0.011118:0.006636:0.004652:0.005077:0.011118:0.003421:0.011682:0.005798:0.003421:0.010434:0.011511:0.004652:0.005798:0.011203:0.004644:0.005798:0.010434:0.011118:0.004642:0.011067:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004652:0.011682:0.011665:0.011665:0.003421:0.003421:0.011067:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738
of naked monoclonal antibodies in solid :@0.131878:0.304249:0.480477:0.304249:0.480477:0.290244:0.131878:0.290244:0.011203:0.005371:0.007256:0.010434:0.011682:0.008586:0.011118:0.011716:0.007261:0.016044:0.011203:0.010434:0.011203:0.011067:0.003421:0.011203:0.010434:0.011682:0.003421:0.007252:0.011682:0.010434:0.005798:0.003421:0.011665:0.011203:0.011716:0.003421:0.011118:0.006636:0.007261:0.003421:0.010434:0.007261:0.006636:0.011203:0.003421:0.003421:0.011716:0.004738
tumors. :@0.131878:0.318384:0.196584:0.318384:0.196584:0.304379:0.131878:0.304379:0.005798:0.010399:0.016044:0.011203:0.005148:0.006636:0.004738:0.004738
Molecular Medicine.:@0.196567:0.318384:0.367234:0.318384:0.367234:0.304379:0.196567:0.304379:0.015719:0.011203:0.003421:0.011118:0.011067:0.010399:0.003421:0.011682:0.005148:0.004738:0.015719:0.011118:0.011716:0.003421:0.011067:0.003421:0.010434:0.011118:0.004738
 2009;15:183.:@0.367234:0.318384:0.471468:0.318384:0.471468:0.304379:0.367234:0.304379:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738
40. :@0.084841:0.332518:0.113269:0.332518:0.113269:0.318513:0.084841:0.318513:0.009476:0.009476:0.004738:0.882722
  Sakamoto H,:@0.131878:0.332518:0.240226:0.332518:0.240226:0.318513:0.131878:0.318513:0.004738:-0.004738:0.008518:0.011682:0.008586:0.011682:0.016044:0.011203:0.005798:0.011203:0.007209:0.011682:0.004738
 et al.:@0.240226:0.332518:0.291419:0.332518:0.291419:0.318513:0.240226:0.318513:0.007218:0.011118:0.005798:0.007218:0.011682:0.003421:0.004738
 Treatment of primary:@0.291419:0.332518:0.475758:0.332518:0.475758:0.318513:0.291419:0.318513:0.007218:0.006773:0.005078:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.007208:0.011203:0.005371:0.007218:0.011665:0.005148:0.003421:0.016044:0.011682:0.005148:0.009168
malignant melanoma of  the  esophagus :@0.131878:0.346653:0.480498:0.346653:0.480498:0.332648:0.131878:0.332648:0.016044:0.011682:0.003421:0.003421:0.011511:0.010434:0.011682:0.010434:0.005798:0.008159:0.016044:0.011118:0.003421:0.011682:0.010434:0.011203:0.016044:0.011682:0.008159:0.011203:0.005371:0.004738:0.003412:0.005798:0.010434:0.011118:0.004738:0.003411:0.011118:0.006636:0.011203:0.011665:0.010434:0.011682:0.011511:0.010399:0.006636:0.004738
with endoscopic injection of interferon-  :@0.131878:0.360788:0.480506:0.360788:0.480506:0.346782:0.131878:0.346782:0.014214:0.003421:0.005798:0.010434:0.007304:0.011118:0.010434:0.011716:0.011203:0.006636:0.011067:0.011203:0.011665:0.003421:0.011067:0.007304:0.003421:0.010434:0.003472:0.011118:0.011067:0.005798:0.003421:0.011203:0.010434:0.007304:0.011203:0.005371:0.007304:0.003421:0.010434:0.005798:0.011118:0.005963:0.005371:0.011118:0.005077:0.011203:0.010434:0.005679:0.008723:0.004738
β:@0.467045:0.362434:0.475768:0.362434:0.475768:0.346571:0.467045:0.346571:0.008723
combined  with  systemic chemotherapy: :@0.131878:0.374922:0.480491:0.374922:0.480491:0.360917:0.131878:0.360917:0.011067:0.011203:0.016044:0.011665:0.003421:0.010434:0.011118:0.011716:0.004738:0.003207:0.014214:0.003421:0.005798:0.010434:0.004738:0.003207:0.006636:0.009168:0.006636:0.005798:0.011118:0.016044:0.003421:0.011067:0.007954:0.011067:0.010434:0.011118:0.016044:0.011195:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
A case report. :@0.131878:0.388916:0.260193:0.388916:0.260193:0.374911:0.131878:0.374911:0.012657:0.007834:0.011067:0.011682:0.006636:0.011118:0.007834:0.005078:0.011118:0.011665:0.011203:0.005148:0.005798:0.004738:0.004738
Gastrointestinal Endosco-:@0.263274:0.388916:0.475761:0.388916:0.475761:0.374911:0.263274:0.374911:0.014915:0.011682:0.006636:0.005798:0.005148:0.011203:0.003421:0.010434:0.005798:0.011118:0.006636:0.005798:0.003421:0.010434:0.011682:0.003421:0.007834:0.009168:0.010434:0.011716:0.011203:0.006636:0.011067:0.011203:0.005679
py.:@0.131878:0.402909:0.157449:0.402909:0.157449:0.388904:0.131878:0.388904:0.011665:0.009168:0.004738
 2003;57:773-777.:@0.157449:0.402909:0.295789:0.402909:0.295789:0.388904:0.157449:0.388904:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
41.:@0.084841:0.416903:0.108531:0.416903:0.108531:0.402898:0.084841:0.402898:0.009476:0.009476:0.004738
  Kujawski LA, Talpaz M. The role of interfer-:@0.131878:0.416903:0.475775:0.416903:0.475775:0.402898:0.131878:0.402898:0.004738:-0.004738:0.010109:0.010399:0.003472:0.011682:0.014214:0.006636:0.008586:0.003421:0.005319:0.007902:0.012657:0.004738:0.005319:0.006397:0.011682:0.003421:0.011665:0.011682:0.007269:0.005319:0.015719:0.004738:0.005319:0.007286:0.010434:0.011118:0.005311:0.005077:0.011203:0.003421:0.011118:0.005319:0.011203:0.005371:0.005319:0.003421:0.010434:0.005798:0.011118:0.005961:0.005371:0.011118:0.005148:0.005679
on-alpha in the treatment of chronic my-:@0.131878:0.430896:0.475761:0.430896:0.475761:0.416891:0.131878:0.416891:0.011203:0.010434:0.005679:0.011682:0.003421:0.011665:0.010434:0.011682:0.005576:0.003421:0.010434:0.005576:0.005798:0.010434:0.011118:0.005576:0.005798:0.005078:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.005566:0.011203:0.005371:0.005576:0.011067:0.010434:0.005075:0.011203:0.010434:0.003421:0.011067:0.005576:0.016044:0.009168:0.005679
eloid leukaemia. :@0.131878:0.444890:0.274871:0.444890:0.274871:0.430885:0.131878:0.430885:0.011118:0.003421:0.011203:0.003421:0.011716:0.005166:0.003421:0.011118:0.010399:0.008586:0.011682:0.011118:0.016044:0.003421:0.011682:0.004738:0.004738
Cytokine & Growth Fac-:@0.275281:0.444890:0.475749:0.444890:0.475749:0.430885:0.275281:0.430885:0.013906:0.009168:0.005798:0.011203:0.008586:0.003421:0.010434:0.011118:0.005150:0.012948:0.005154:0.014915:0.005148:0.011203:0.014214:0.005798:0.010434:0.005147:0.008296:0.011682:0.011067:0.005679
tor Reviews.:@0.131878:0.458883:0.229869:0.458883:0.229869:0.444878:0.131878:0.444878:0.005798:0.011203:0.005148:0.004738:0.010382:0.011118:0.009476:0.003421:0.011118:0.014214:0.006636:0.004738
 2007;18:459-471.:@0.229869:0.458883:0.368209:0.458883:0.368209:0.444878:0.229869:0.444878:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
42.:@0.084841:0.472877:0.108531:0.472877:0.108531:0.458872:0.084841:0.458872:0.009476:0.009476:0.004738
  George PM, Badiger R, Alazawi W, :@0.131878:0.472877:0.429922:0.472877:0.429922:0.458872:0.131878:0.458872:0.004738:-0.004738:0.014915:0.011118:0.011203:0.005148:0.011511:0.011118:0.006893:0.010126:0.015719:0.004738:0.006893:0.009818:0.011682:0.011716:0.003421:0.011511:0.011118:0.005148:0.006893:0.010382:0.004738:0.006893:0.012657:0.003421:0.011682:0.007269:0.011682:0.014214:0.003421:0.006910:0.014607:0.004738:0.004738
et al:@0.432077:0.472877:0.470989:0.472877:0.470989:0.458872:0.432077:0.458872:0.011118:0.005798:0.006893:0.011682:0.003421
.:@0.470989:0.472877:0.475727:0.472877:0.475727:0.458872:0.470989:0.458872:0.004738
Pharmacology and therapeutic potential :@0.131878:0.486870:0.480487:0.486870:0.480487:0.472865:0.131878:0.472865:0.010126:0.010434:0.011682:0.005617:0.016044:0.011682:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004899:0.011682:0.010434:0.011716:0.004900:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.011118:0.010399:0.005798:0.003421:0.011067:0.004892:0.011665:0.011203:0.005798:0.011118:0.010434:0.005798:0.003421:0.011682:0.003421:0.004738
of interferons. :@0.131878:0.500864:0.248458:0.500864:0.248458:0.486859:0.131878:0.486859:0.011203:0.005371:0.003960:0.003421:0.010434:0.005798:0.011118:0.005959:0.005371:0.011118:0.005078:0.011203:0.010434:0.006636:0.004738:0.004738
Pharmacology & Therapeu-:@0.247675:0.500864:0.475767:0.500864:0.475767:0.486859:0.247675:0.486859:0.010126:0.010434:0.011682:0.005148:0.016044:0.011682:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.003956:0.012948:0.003968:0.007286:0.010434:0.011118:0.005148:0.011682:0.011665:0.011118:0.010399:0.005679
tics.:@0.131878:0.514858:0.163538:0.514858:0.163538:0.500852:0.131878:0.500852:0.005798:0.003421:0.011067:0.006636:0.004738
 2012;135:44-53.:@0.163538:0.514858:0.292403:0.514858:0.292403:0.500852:0.163538:0.500852:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
43.:@0.084841:0.528851:0.108531:0.528851:0.108531:0.514846:0.084841:0.514846:0.009476:0.009476:0.004738
  Interferon  alfacon-1. June  13, 2005. Up-:@0.131878:0.528851:0.475749:0.528851:0.475749:0.514846:0.131878:0.514846:0.004738:-0.004738:0.003866:0.010434:0.005798:0.011118:0.005952:0.005371:0.011118:0.005077:0.011203:0.010434:0.004738:0.003989:0.011682:0.003421:0.005371:0.011682:0.011067:0.011203:0.010434:0.005679:0.009476:0.004738:0.008740:0.008244:0.010399:0.010434:0.011118:0.004738:0.003990:0.009476:0.009476:0.004738:0.008740:0.009476:0.009476:0.009476:0.009476:0.004738:0.008740:0.011203:0.011665:0.005679
dated on September 29, 2010 Ed. (Drug-:@0.131878:0.542845:0.475744:0.542845:0.475744:0.528839:0.131878:0.528839:0.011716:0.011682:0.005798:0.011118:0.011716:0.006500:0.011203:0.010434:0.006500:0.008518:0.011118:0.011665:0.005798:0.011118:0.016044:0.011665:0.011118:0.005148:0.006500:0.009476:0.009476:0.004738:0.006500:0.009476:0.009476:0.009476:0.009476:0.006517:0.009168:0.011716:0.004738:0.006500:0.006312:0.012726:0.005148:0.010399:0.011511:0.005679
Bank, published online 2010).:@0.131878:0.556838:0.370809:0.556838:0.370809:0.542833:0.131878:0.542833:0.009818:0.011682:0.010434:0.008586:0.004738:0.004738:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
44.:@0.084841:0.570832:0.108531:0.570832:0.108531:0.556826:0.084841:0.556826:0.009476:0.009476:0.004738
  Interferon Alfa-2a, Recombinant. June 13, :@0.131878:0.570832:0.480486:0.570832:0.480486:0.556826:0.131878:0.556826:0.004738:-0.004738:0.003866:0.010434:0.005798:0.011118:0.005952:0.005371:0.011118:0.005077:0.011203:0.010434:0.004228:0.012657:0.003421:0.005371:0.011682:0.005679:0.009476:0.011682:0.004738:0.004242:0.010382:0.011118:0.011067:0.011203:0.016044:0.011665:0.003421:0.010434:0.011682:0.010434:0.005798:0.004738:0.004226:0.008244:0.010399:0.010434:0.011118:0.004226:0.009476:0.009476:0.004738:0.004738
2005. Updated on September 29, 2010 Ed. :@0.131878:0.584825:0.480481:0.584825:0.480481:0.570820:0.131878:0.570820:0.009476:0.009476:0.009476:0.009476:0.004738:0.004223:0.011203:0.011665:0.011716:0.011682:0.005798:0.011118:0.011716:0.004208:0.011203:0.010434:0.004208:0.008518:0.011118:0.011665:0.005798:0.011118:0.016044:0.011665:0.011118:0.005148:0.004208:0.009476:0.009476:0.004738:0.004208:0.009476:0.009476:0.009476:0.009476:0.004225:0.009168:0.011716:0.004738:0.004738
(DrugBank, published online 2010).:@0.131878:0.598819:0.416905:0.598819:0.416905:0.584813:0.131878:0.584813:0.006312:0.012726:0.005148:0.010399:0.011511:0.009818:0.011682:0.010434:0.008586:0.004738:0.004738:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
45.:@0.084841:0.612812:0.108531:0.612812:0.108531:0.598807:0.084841:0.598807:0.009476:0.009476:0.004738
  Interferon Alfa-2b, Recombinant. June 13, :@0.131878:0.612812:0.480481:0.612812:0.480481:0.598807:0.131878:0.598807:0.004738:-0.004738:0.003866:0.010434:0.005798:0.011118:0.005952:0.005371:0.011118:0.005077:0.011203:0.010434:0.004232:0.012657:0.003421:0.005371:0.011682:0.005679:0.009476:0.011665:0.004738:0.004242:0.010382:0.011118:0.011067:0.011203:0.016044:0.011665:0.003421:0.010434:0.011682:0.010434:0.005798:0.004738:0.004230:0.008244:0.010399:0.010434:0.011118:0.004232:0.009476:0.009476:0.004738:0.004738
2005. Updated on September 29, 2010 Ed. :@0.131878:0.626806:0.480481:0.626806:0.480481:0.612800:0.131878:0.612800:0.009476:0.009476:0.009476:0.009476:0.004738:0.004223:0.011203:0.011665:0.011716:0.011682:0.005798:0.011118:0.011716:0.004208:0.011203:0.010434:0.004208:0.008518:0.011118:0.011665:0.005798:0.011118:0.016044:0.011665:0.011118:0.005148:0.004208:0.009476:0.009476:0.004738:0.004208:0.009476:0.009476:0.009476:0.009476:0.004225:0.009168:0.011716:0.004738:0.004738
(DrugBank, published online 2010).:@0.131878:0.640799:0.416905:0.640799:0.416905:0.626794:0.131878:0.626794:0.006312:0.012726:0.005148:0.010399:0.011511:0.009818:0.011682:0.010434:0.008586:0.004738:0.004738:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
46.:@0.084841:0.654793:0.108531:0.654793:0.108531:0.640787:0.084841:0.640787:0.009476:0.009476:0.004738
  Aldesleukin.  June  13, 2005. Updated  on:@0.131878:0.654793:0.475753:0.654793:0.475753:0.640787:0.131878:0.640787:0.004738:-0.004738:0.012657:0.003421:0.011716:0.011118:0.006636:0.003421:0.011118:0.010399:0.008586:0.003421:0.010434:0.004738:0.004738:0.003883:0.008244:0.010399:0.010434:0.011118:0.004738:0.003884:0.009476:0.009476:0.004738:0.008638:0.009476:0.009476:0.009476:0.009476:0.004738:0.008638:0.011203:0.011665:0.011716:0.011682:0.005798:0.011118:0.011716:0.004738:0.003890:0.011203:0.010434
December 18, 2012 Ed. (DrugBank, pub-:@0.131878:0.668786:0.475753:0.668786:0.475753:0.654781:0.131878:0.654781:0.012726:0.011118:0.011067:0.011118:0.016044:0.011665:0.011118:0.005148:0.007170:0.009476:0.009476:0.004738:0.007184:0.009476:0.009476:0.009476:0.009476:0.007184:0.009168:0.011716:0.004738:0.007184:0.006312:0.012726:0.005148:0.010399:0.011511:0.009818:0.011682:0.010434:0.008586:0.004738:0.007172:0.011665:0.010399:0.011665:0.005679
lished online, 2012).:@0.131878:0.682780:0.291821:0.682780:0.291821:0.668774:0.131878:0.668774:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
47.:@0.084841:0.696773:0.108538:0.696773:0.108538:0.682768:0.084841:0.682768:0.009479:0.009479:0.004738
  Proleukin. Aldesleukin for injection. (Availa-:@0.131878:0.696773:0.475779:0.696773:0.475779:0.682768:0.131878:0.682768:0.004738:-0.004738:0.009818:0.004772:0.010895:0.003113:0.010810:0.010092:0.008279:0.003113:0.010126:0.004430:0.006294:0.012349:0.003113:0.011409:0.010810:0.006329:0.003113:0.010810:0.010092:0.008279:0.003113:0.010126:0.006294:0.005063:0.010895:0.004841:0.006286:0.003113:0.010126:0.003164:0.010810:0.010759:0.005490:0.003113:0.010895:0.010126:0.004430:0.006294:0.006004:0.011092:0.009168:0.011374:0.003113:0.003113:0.011374:0.005679
ble from  http://patient.cancerconsult-:@0.131878:0.710767:0.475760:0.710767:0.475760:0.696762:0.131878:0.696762:0.011357:0.003113:0.010810:0.010023:0.005901:0.005609:0.011730:0.016574:0.004738:0.006111:0.010964:0.006329:0.006329:0.012195:0.005268:0.008005:0.008005:0.012195:0.012213:0.006329:0.003951:0.011648:0.010964:0.006329:0.005268:0.011597:0.012213:0.010964:0.011597:0.011648:0.005557:0.011597:0.011734:0.010964:0.007167:0.010930:0.003951:0.006329:0.005679
ants. com).:@0.131878:0.724760:0.226380:0.724760:0.226380:0.710755:0.131878:0.710755:0.012213:0.010964:0.006329:0.007167:0.005268:0.004430:0.010759:0.010895:0.015736:0.006004:0.004738
48.:@0.084841:0.738754:0.108531:0.738754:0.108531:0.724749:0.084841:0.724749:0.009476:0.009476:0.004738
  Campbell P, Marcus R. Monoclonal anti-:@0.131878:0.738754:0.475773:0.738754:0.475773:0.724749:0.131878:0.724749:0.004738:-0.004738:0.013906:0.011682:0.016044:0.011665:0.011665:0.011118:0.003421:0.003421:0.007167:0.008017:0.004738:0.007150:0.015719:0.011682:0.005029:0.011067:0.010399:0.006636:0.007150:0.010382:0.004738:0.007150:0.015719:0.011203:0.010434:0.011203:0.011067:0.003421:0.011203:0.010434:0.011682:0.003421:0.007150:0.011682:0.010434:0.005798:0.003421:0.005679
body therapy for lymphoma. :@0.131878:0.752747:0.388187:0.752747:0.388187:0.738742:0.131878:0.738742:0.011665:0.011203:0.011716:0.009168:0.008894:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.008894:0.005371:0.011203:0.005148:0.008894:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738
Blood  Re-:@0.392343:0.752747:0.475768:0.752747:0.475768:0.738742:0.392343:0.738742:0.009818:0.003421:0.011203:0.011203:0.011716:0.004738:0.004146:0.010382:0.011118:0.005679
views.:@0.131878:0.766741:0.181481:0.766741:0.181481:0.752736:0.131878:0.752736:0.009476:0.003421:0.011118:0.014214:0.006636:0.004738
 2003;17:143-152.:@0.181481:0.766741:0.319821:0.766741:0.319821:0.752736:0.181481:0.752736:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
49. :@0.084841:0.780734:0.113269:0.780734:0.113269:0.766729:0.084841:0.766729:0.009479:0.009479:0.004731:0.230772
  Nückel H, Frey UH, Röth A, :@0.131878:0.780734:0.338393:0.780734:0.338393:0.766729:0.131878:0.766729:0.004738:-0.004738:0.012349:0.010092:0.010759:0.008279:0.010810:0.003113:0.003609:0.011374:0.004430:0.003618:0.007988:0.004770:0.010810:0.008860:0.003618:0.010895:0.011374:0.004430:0.003618:0.010074:0.010895:0.005490:0.010126:0.003616:0.012349:0.004430:0.004738
et al.:@0.337250:0.780734:0.376394:0.780734:0.376394:0.766729:0.337250:0.766729:0.010810:0.005490:0.003618:0.011374:0.003113:0.004738
 Alemtuzum-:@0.376086:0.780734:0.475761:0.780734:0.475761:0.766729:0.376086:0.766729:0.003618:0.012349:0.003113:0.010810:0.015736:0.005490:0.010092:0.006961:0.010092:0.015736:0.005679
ab induces enhanced apoptosis :@0.131878:0.794728:0.402418:0.794728:0.402418:0.780723:0.131878:0.780723:0.011374:0.011357:0.005918:0.003113:0.010126:0.011409:0.010092:0.010759:0.010810:0.006329:0.005918:0.010810:0.010126:0.010126:0.011374:0.010126:0.010759:0.010810:0.011409:0.005918:0.011374:0.011357:0.010895:0.011357:0.005490:0.010895:0.006329:0.003113:0.006329:0.004738
in vitro:@0.403598:0.794728:0.456570:0.794728:0.456570:0.780723:0.403598:0.780723:0.003113:0.010126:0.005918:0.009168:0.003113:0.005490:0.004841:0.011203
 in :@0.456262:0.794728:0.480463:0.794728:0.480463:0.780723:0.456262:0.780723:0.005918:0.003113:0.010432:0.004738
B-cells from patients with chronic lympho-:@0.131878:0.808721:0.475748:0.808721:0.475748:0.794716:0.131878:0.794716:0.009510:0.005371:0.010759:0.010810:0.003113:0.003113:0.006329:0.007073:0.005063:0.004769:0.010895:0.015736:0.007073:0.011357:0.011374:0.005490:0.003113:0.010810:0.010126:0.005490:0.006329:0.007073:0.013906:0.003113:0.005490:0.010126:0.007073:0.010759:0.010126:0.004770:0.010895:0.010126:0.003113:0.010759:0.007073:0.003113:0.008860:0.015736:0.011357:0.010126:0.010895:0.005679
cytic  leukaemia  by  antibody-dependent :@0.131878:0.822856:0.480479:0.822856:0.480479:0.808851:0.131878:0.808851:0.010759:0.008860:0.005490:0.003113:0.010759:0.004738:0.005034:0.003113:0.010810:0.010092:0.008279:0.011374:0.010810:0.015736:0.003113:0.011374:0.004738:0.005034:0.011357:0.008860:0.004738:0.005034:0.011374:0.010126:0.005490:0.003113:0.011357:0.010895:0.011409:0.008860:0.005371:0.011409:0.010810:0.011357:0.010810:0.010126:0.011409:0.010810:0.010126:0.005797:0.004738
cellular cytotoxicity. :@0.131878:0.836991:0.299296:0.836991:0.299296:0.822985:0.131878:0.822985:0.010759:0.010810:0.003113:0.003113:0.010092:0.003113:0.011374:0.004841:0.009407:0.010759:0.008860:0.005490:0.010895:0.005490:0.010895:0.007902:0.003113:0.010759:0.003113:0.005490:0.008860:0.004430:0.004738
European Journal of :@0.303965:0.836991:0.480516:0.836991:0.480516:0.822985:0.303965:0.822985:0.008860:0.010092:0.004841:0.010895:0.011357:0.010810:0.011374:0.010126:0.009407:0.007936:0.010895:0.010092:0.004841:0.010126:0.011374:0.003113:0.009407:0.010895:0.005371:0.004738
Pharmacology.:@0.131878:0.851125:0.255611:0.851125:0.255611:0.837120:0.131878:0.837120:0.009818:0.010126:0.011374:0.004841:0.015736:0.011374:0.010759:0.010895:0.003113:0.010895:0.011203:0.008860:0.004738
 2005; 514:217-224.:@0.255303:0.851125:0.402315:0.851125:0.402315:0.837120:0.255303:0.837120:0.004430:0.009168:0.009168:0.009168:0.009168:0.004430:0.004430:0.009168:0.009168:0.009168:0.004430:0.009168:0.009168:0.009168:0.005371:0.009168:0.009168:0.009168:0.004738
50.:@0.084841:0.865260:0.108531:0.865260:0.108531:0.851255:0.084841:0.851255:0.009476:0.009476:0.004738
  GlaxoSmithKline.  Tykerb  (lapatinib)  tab-:@0.131878:0.865260:0.475739:0.865260:0.475739:0.851255:0.131878:0.851255:0.004738:-0.004738:0.014915:0.003421:0.011682:0.008210:0.011203:0.008518:0.016044:0.003421:0.005798:0.010434:0.010109:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.006346:0.007367:0.009168:0.008586:0.011118:0.005148:0.011665:0.004738:0.006353:0.006312:0.003421:0.011682:0.011665:0.011682:0.005798:0.003421:0.010434:0.003421:0.011665:0.006312:0.004738:0.006373:0.005798:0.011682:0.011665:0.005679
lets. (FDA, published online, 2007).:@0.131878:0.879395:0.411466:0.879395:0.411466:0.865389:0.131878:0.865389:0.003421:0.011118:0.005798:0.006636:0.004738:0.004738:0.006312:0.008296:0.012726:0.012657:0.004738:0.004738:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
51.:@0.084841:0.893529:0.108538:0.893529:0.108538:0.879524:0.084841:0.879524:0.009479:0.009479:0.004738
  Millennium  Pharmaceuticals,  I.  Velcade:@0.131878:0.893529:0.475737:0.893529:0.475737:0.879524:0.131878:0.879524:0.004738:-0.004738:0.015411:0.003113:0.003113:0.003113:0.010810:0.010126:0.010126:0.003113:0.010092:0.015736:0.004738:0.009442:0.009818:0.010126:0.011374:0.005313:0.015736:0.011374:0.010759:0.010810:0.010092:0.005490:0.003113:0.010759:0.011374:0.003113:0.006329:0.004430:0.004738:0.009448:0.003558:0.004430:0.004738:0.009450:0.009974:0.010810:0.003113:0.010759:0.011374:0.011409:0.011118
(bortezomib) for injection for  subcutane-:@0.131878:0.907664:0.475767:0.907664:0.475767:0.893659:0.131878:0.893659:0.006005:0.011361:0.010892:0.004835:0.005798:0.011118:0.007269:0.011203:0.016044:0.003421:0.011665:0.006312:0.007321:0.005371:0.011203:0.005148:0.007321:0.003421:0.010434:0.003472:0.011118:0.011067:0.005798:0.003421:0.011203:0.010434:0.007321:0.005371:0.011203:0.005148:0.004738:0.002574:0.006636:0.010399:0.011665:0.011067:0.010399:0.005798:0.011682:0.010434:0.011118:0.005679
ous or intravenous use. 15th Ed. (Published :@0.131878:0.921798:0.480491:0.921798:0.480491:0.907793:0.131878:0.907793:0.011203:0.010399:0.006636:0.004096:0.011203:0.005148:0.004091:0.003421:0.010434:0.005798:0.005148:0.011682:0.009476:0.011118:0.010434:0.011203:0.010399:0.006636:0.004093:0.010399:0.006636:0.011118:0.004738:0.004096:0.009476:0.009476:0.005798:0.010434:0.004105:0.009168:0.011716:0.004738:0.004105:0.006312:0.010126:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738
online, 2012).:@0.131878:0.935933:0.240337:0.935933:0.240337:0.921928:0.131878:0.921928:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
52.:@0.524235:0.078083:0.547925:0.078083:0.547925:0.064078:0.524235:0.064078:0.009476:0.009476:0.004738
  Zagouri F, Sergentanis TN, Chrysikos D, :@0.571272:0.078083:0.896098:0.078083:0.896098:0.064078:0.571272:0.064078:0.004738:-0.004738:0.008210:0.011682:0.011511:0.011203:0.010399:0.005148:0.003421:0.006893:0.006205:0.004738:0.006893:0.008518:0.011118:0.005160:0.011511:0.011118:0.010434:0.005798:0.011682:0.010434:0.003421:0.006636:0.006893:0.007286:0.012657:0.004738:0.006881:0.013906:0.010434:0.005148:0.009168:0.006636:0.003421:0.008586:0.011203:0.006636:0.006893:0.012726:0.004738:0.004738
et:@0.898253:0.078083:0.915169:0.078083:0.915169:0.064078:0.898253:0.064078:0.011118:0.005798
al:@0.571272:0.092383:0.586375:0.092383:0.586375:0.078377:0.571272:0.078377:0.011682:0.003421
. mTOR inhibitors in breast cancer: a sys-:@0.586375:0.092383:0.915142:0.092383:0.915142:0.078377:0.586375:0.078377:0.004738:0.004709:0.016044:0.007286:0.014864:0.010382:0.004709:0.003421:0.010434:0.010434:0.003421:0.011665:0.003421:0.005798:0.011203:0.005148:0.006636:0.004712:0.003421:0.010434:0.004712:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.004712:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004705:0.011682:0.004721:0.006636:0.009168:0.006636:0.005679
tematic review. :@0.571272:0.106682:0.707986:0.106682:0.707986:0.092677:0.571272:0.092677:0.005798:0.011118:0.016044:0.011682:0.005798:0.003421:0.011067:0.007885:0.005078:0.011118:0.009476:0.003421:0.011118:0.014214:0.004738:0.004738
Gynecologic Oncology.:@0.711133:0.106682:0.915154:0.106682:0.915154:0.092677:0.711133:0.092677:0.014915:0.009168:0.010434:0.011118:0.011067:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.007885:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738
2012;127:662-672.:@0.571272:0.120981:0.714350:0.120981:0.714350:0.106976:0.571272:0.106976:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
53.:@0.524235:0.135280:0.547932:0.135280:0.547932:0.121275:0.524235:0.121275:0.009479:0.009479:0.004738
  Lichtman SM, Skirvin  JA, Vemulapalli S.:@0.571272:0.135280:0.915172:0.135280:0.915172:0.121275:0.571272:0.121275:0.004738:-0.004738:0.007697:0.003216:0.010861:0.010228:0.005593:0.015839:0.011477:0.010228:0.012093:0.008313:0.015514:0.004533:0.012093:0.008313:0.008381:0.003216:0.004943:0.009271:0.003216:0.010228:0.004738:0.007355:0.008039:0.012452:0.004533:0.012093:0.010074:0.010913:0.015839:0.010194:0.003216:0.011477:0.011460:0.011477:0.003216:0.003216:0.003216:0.012093:0.008313:0.004738
Pharmacology of antineoplastic agents in :@0.571272:0.149580:0.919883:0.149580:0.919883:0.135574:0.571272:0.135574:0.009917:0.010227:0.011479:0.005415:0.016044:0.011682:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004037:0.011203:0.005371:0.004037:0.011682:0.010434:0.005798:0.003421:0.010434:0.011118:0.011203:0.011665:0.003421:0.011682:0.006636:0.005798:0.003421:0.011067:0.004037:0.011682:0.011511:0.011118:0.010434:0.005798:0.006636:0.004037:0.003421:0.010434:0.004738
older cancer patients. :@0.571272:0.163879:0.762969:0.163879:0.762969:0.149874:0.571272:0.149874:0.011203:0.003421:0.011716:0.011118:0.005148:0.006277:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.006269:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738:0.004738
Critical Reviews in:@0.764509:0.163879:0.915147:0.163879:0.915147:0.149874:0.764509:0.149874:0.013906:0.005148:0.003421:0.005798:0.003421:0.011067:0.011682:0.003421:0.006277:0.010382:0.011118:0.009476:0.003421:0.011118:0.014214:0.006636:0.006277:0.003421:0.010434
Oncology/Hematology.:@0.571272:0.178178:0.769187:0.178178:0.769187:0.164173:0.571272:0.164173:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.007475:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738
 2003;46:101-114.:@0.769170:0.178178:0.907510:0.178178:0.907510:0.164173:0.769170:0.164173:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
54.:@0.524235:0.192477:0.547925:0.192477:0.547925:0.178472:0.524235:0.178472:0.009476:0.009476:0.004738
  Pan B. Lentzsch S. The application and bi-:@0.571272:0.192477:0.915138:0.192477:0.915138:0.178472:0.571272:0.178472:0.004738:-0.004738:0.010126:0.011682:0.010434:0.004892:0.009818:0.004738:0.004892:0.007902:0.011118:0.010434:0.005798:0.007269:0.006636:0.011067:0.010434:0.004892:0.008518:0.004738:0.004892:0.007286:0.010434:0.011118:0.004892:0.011682:0.011665:0.011665:0.003421:0.003421:0.011067:0.011682:0.005798:0.003421:0.011203:0.010434:0.004909:0.011682:0.010434:0.011716:0.004892:0.011665:0.003421:0.005679
ology of immunomodulatory drugs (IMiDs):@0.571272:0.206777:0.915145:0.206777:0.915145:0.192771:0.571272:0.192771:0.011203:0.003421:0.011203:0.011511:0.009168:0.004262:0.011203:0.005371:0.004262:0.003421:0.016044:0.016044:0.010399:0.010434:0.011203:0.016044:0.011203:0.011716:0.010399:0.003421:0.011682:0.005798:0.011203:0.005148:0.009168:0.004259:0.011716:0.005148:0.010399:0.011511:0.006636:0.004276:0.006312:0.003866:0.015719:0.003421:0.012726:0.006636:0.006312
in  cancer. :@0.571272:0.221076:0.659375:0.221076:0.659375:0.207071:0.571272:0.207071:0.003424:0.010432:0.004738:0.002930:0.010759:0.011374:0.010126:0.010759:0.010810:0.003583:0.004430:0.004738
Pharmacology  &  Therapeutics.:@0.661994:0.221076:0.915169:0.221076:0.915169:0.207071:0.661994:0.207071:0.009818:0.010126:0.011374:0.004841:0.015736:0.011374:0.010759:0.010895:0.003113:0.010895:0.011203:0.008860:0.004738:0.002624:0.012640:0.004738:0.002624:0.006979:0.010126:0.010810:0.004841:0.011374:0.011357:0.010810:0.010092:0.005490:0.003113:0.010759:0.006329:0.004738
2012; 136:56-68.:@0.571272:0.235375:0.698301:0.235375:0.698301:0.221370:0.571272:0.221370:0.009171:0.009171:0.009171:0.009171:0.004428:0.004430:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
55.:@0.524235:0.249674:0.547316:0.249674:0.547316:0.235669:0.524235:0.235669:0.009171:0.009171:0.004738
  ProStrakan Inc. Fareston  (toremifene cit-:@0.571272:0.249674:0.915163:0.249643:0.915163:0.235637:0.571272:0.235669:0.004738:-0.004738:0.009613:0.004567:0.010690:0.008005:0.005285:0.004635:0.011169:0.008073:0.011169:0.009921:0.010913:0.003352:0.009921:0.010553:0.004225:0.010913:0.007782:0.011169:0.004565:0.010605:0.006123:0.005285:0.010690:0.010434:0.006613:0.010913:0.005798:0.005285:0.010690:0.004565:0.010605:0.015531:0.002908:0.004858:0.010605:0.009921:0.010605:0.010913:0.010553:0.002908:0.005285:0.202315
®:@0.770393:0.244648:0.777842:0.244648:0.777842:0.236483:0.770393:0.236483:0.007449
rate). (fareston.com, published online, 2012).:@0.571282:0.263942:0.915163:0.263942:0.915163:0.249937:0.571282:0.249937:0.004635:0.011169:0.005285:0.010605:0.005798:0.004225:0.003626:0.005798:0.004858:0.011169:0.004565:0.010605:0.006123:0.005285:0.010690:0.009921:0.004225:0.010553:0.010690:0.015531:0.004225:0.003626:0.011152:0.009886:0.011152:0.002908:0.002908:0.006123:0.009921:0.010605:0.011203:0.003626:0.010690:0.009921:0.002908:0.002908:0.009921:0.010605:0.004225:0.003626:0.008963:0.008963:0.008963:0.008963:0.005798:0.004738
56. :@0.524245:0.278241:0.552672:0.278241:0.552672:0.264236:0.524245:0.264236:0.009476:0.009476:0.004738:0.004738
  Cardoso  F,:@0.571282:0.278241:0.662195:0.278241:0.662195:0.264236:0.571282:0.264236:0.004738:-0.004738:0.013906:0.011682:0.005046:0.011716:0.011203:0.006636:0.011203:0.004738:0.003838:0.006205:0.004738
 et  al.:@0.662195:0.278241:0.716114:0.278241:0.716114:0.264236:0.662195:0.264236:0.008586:0.011118:0.005798:0.004738:0.003838:0.011682:0.003421:0.004738
 A  review of  the  treat-:@0.716114:0.278241:0.915168:0.278241:0.915168:0.264236:0.716114:0.264236:0.008586:0.012657:0.004738:0.003837:0.005078:0.011118:0.009476:0.003421:0.011118:0.014214:0.008586:0.011203:0.005371:0.004738:0.003838:0.005798:0.010434:0.011118:0.004738:0.003835:0.005798:0.005077:0.011118:0.011682:0.005798:0.005679
ment of endocrine responsive metastatic:@0.571282:0.292541:0.915161:0.292541:0.915161:0.278535:0.571282:0.278535:0.016044:0.011118:0.010434:0.005798:0.005602:0.011203:0.005371:0.005610:0.011118:0.010434:0.011716:0.011203:0.011067:0.005148:0.003421:0.010423:0.011118:0.005610:0.005078:0.011118:0.006636:0.011665:0.011203:0.010434:0.006636:0.003421:0.009476:0.011118:0.005610:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067
breast cancer in postmenopausal wom-:@0.571282:0.306840:0.915148:0.306840:0.915148:0.292834:0.571282:0.292834:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.007697:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.007697:0.003421:0.010434:0.007697:0.011665:0.011203:0.006636:0.005798:0.016044:0.011118:0.010434:0.011203:0.011665:0.011682:0.010399:0.006636:0.011682:0.003421:0.007697:0.014214:0.011203:0.016044:0.005679
en. :@0.571282:0.321139:0.602309:0.321139:0.602309:0.307134:0.571282:0.307134:0.011118:0.010434:0.004738:0.004738
Cancer Treatment Reviews:@0.602292:0.321139:0.825914:0.321139:0.825914:0.307134:0.602292:0.307134:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.007286:0.005148:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738:0.010382:0.011118:0.009476:0.003421:0.011118:0.014214:0.006636
. 2012.:@0.825897:0.321139:0.878014:0.321139:0.878014:0.307134:0.825897:0.307134:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738
57. :@0.524245:0.335438:0.552672:0.335438:0.552672:0.321433:0.524245:0.321433:0.009476:0.009476:0.004738:0.439071
  AstraZeneca.  FASLODEX . (AstraZeneca,:@0.571282:0.335438:0.915168:0.335427:0.915168:0.321422:0.571282:0.321433:0.004738:-0.004738:0.012657:0.006636:0.005798:0.005148:0.011682:0.008210:0.011118:0.010434:0.011118:0.011067:0.011682:0.004738:0.004738:0.005901:0.007266:0.012657:0.008518:0.007902:0.014864:0.012726:0.009168:0.010417:0.007447:0.004738:0.010656:0.006312:0.012657:0.006636:0.005798:0.005148:0.011682:0.008210:0.011118:0.010434:0.011118:0.011067:0.011682:0.076591
®:@0.775724:0.330433:0.783173:0.330433:0.783173:0.322268:0.775724:0.322268:0.007449
published online, 2012).:@0.571285:0.349727:0.764957:0.349727:0.764957:0.335721:0.571285:0.335721:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
58.:@0.524248:0.364026:0.547937:0.364026:0.547937:0.350021:0.524248:0.350021:0.009476:0.009476:0.004738
  Macciò A, Madeddu C, Mantovani G.:@0.571285:0.364026:0.915168:0.364026:0.915168:0.350021:0.571285:0.350021:0.004738:-0.004738:0.015719:0.011682:0.011067:0.011067:0.003421:0.011203:0.010023:0.012657:0.004738:0.010023:0.015719:0.011682:0.011716:0.011118:0.011716:0.011716:0.010399:0.010023:0.013906:0.004738:0.010023:0.015719:0.011682:0.010434:0.005798:0.011203:0.009476:0.011682:0.010434:0.003421:0.010023:0.014915:0.034994
Adipose tissue as target  organ  in the:@0.571285:0.378325:0.915187:0.378325:0.915187:0.364320:0.571285:0.364320:0.012657:0.011716:0.003421:0.011665:0.011203:0.006636:0.011118:0.011819:0.005798:0.003421:0.006636:0.006636:0.010399:0.011118:0.011819:0.011682:0.006636:0.011819:0.005798:0.011682:0.005166:0.011511:0.011118:0.005798:0.004738:0.007066:0.011203:0.005159:0.011511:0.011682:0.010434:0.004738:0.007071:0.003421:0.010434:0.011819:0.005798:0.010434:0.020556
treatment  of hormone-dependent breast:@0.571285:0.392624:0.915192:0.392624:0.915192:0.378619:0.571285:0.378619:0.005797:0.005077:0.011118:0.011684:0.005795:0.016044:0.011116:0.010432:0.005797:0.004738:0.003140:0.010895:0.005063:0.007577:0.010126:0.010895:0.005313:0.015736:0.010895:0.010126:0.010810:0.005371:0.011409:0.010810:0.011357:0.010810:0.010126:0.011409:0.010810:0.010126:0.005490:0.007577:0.011357:0.004770:0.010810:0.011374:0.006329:0.005798
cancer:  new therapeutic perspectives.:@0.571285:0.406924:0.915158:0.406924:0.915158:0.392918:0.571285:0.392918:0.010759:0.011376:0.010122:0.010759:0.010808:0.004837:0.004428:0.004738:0.007955:0.010122:0.010808:0.013908:0.012999:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.011118:0.010399:0.005798:0.003421:0.011067:0.012999:0.011665:0.011118:0.005148:0.006636:0.011665:0.011118:0.011067:0.005798:0.003421:0.009476:0.011118:0.006636:0.004738
Obesity Reviews.:@0.571285:0.421223:0.709796:0.421223:0.709796:0.407218:0.571285:0.407218:0.014864:0.011665:0.011118:0.006636:0.003421:0.005798:0.009168:0.004738:0.010382:0.011118:0.009476:0.003421:0.011118:0.014214:0.006636:0.004738
 2009;10:660-670.:@0.709813:0.421223:0.848153:0.421223:0.848153:0.407218:0.709813:0.407218:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
59.:@0.524248:0.435522:0.547937:0.435522:0.547937:0.421517:0.524248:0.421517:0.009476:0.009476:0.004738
  Jänicke F. Are all aromatase inhibitors the:@0.571285:0.435522:0.915165:0.435522:0.915165:0.421517:0.571285:0.421517:0.004738:-0.004738:0.008244:0.011682:0.010434:0.003421:0.011067:0.008586:0.011118:0.005063:0.006939:0.004738:0.005066:0.012657:0.005078:0.011118:0.005066:0.011682:0.003421:0.003421:0.005080:0.011682:0.005080:0.011203:0.016044:0.011682:0.005798:0.011682:0.006636:0.011118:0.005068:0.003421:0.010434:0.010434:0.003421:0.011665:0.003421:0.005798:0.011203:0.005148:0.006636:0.005071:0.005798:0.010434:0.011118
same? A review of the current evidence.:@0.571285:0.449821:0.915166:0.449821:0.915166:0.435816:0.571285:0.435816:0.006636:0.011682:0.016044:0.011118:0.010109:0.005679:0.012657:0.005670:0.005078:0.011118:0.009476:0.003421:0.011118:0.014214:0.005679:0.011203:0.005371:0.005679:0.005798:0.010434:0.011118:0.005670:0.011067:0.010399:0.005148:0.005071:0.011118:0.010434:0.005798:0.005670:0.011118:0.009476:0.003421:0.011716:0.011118:0.010434:0.011067:0.011118:0.004738
The Breast.:@0.571285:0.464121:0.659800:0.464121:0.659800:0.450115:0.571285:0.450115:0.007286:0.010434:0.011118:0.004738:0.009818:0.005148:0.011118:0.011682:0.006636:0.005798:0.004738
 2004;13:10-18.:@0.659783:0.464121:0.779171:0.464121:0.779171:0.450115:0.659783:0.450115:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
60.:@0.524248:0.478420:0.547944:0.478420:0.547944:0.464415:0.524248:0.464415:0.009479:0.009479:0.004738
  Accord Healthcare Inc. Anastrozole. Vol.:@0.571285:0.478420:0.915183:0.478420:0.915183:0.464415:0.571285:0.464415:0.004738:-0.004738:0.012127:0.010536:0.010536:0.010673:0.004516:0.011186:0.011409:0.011152:0.010588:0.011152:0.002891:0.005268:0.009903:0.010536:0.011152:0.004548:0.010588:0.011409:0.003335:0.009903:0.010536:0.004208:0.011409:0.012127:0.009903:0.011152:0.006106:0.005268:0.004548:0.010673:0.006739:0.010673:0.002891:0.010588:0.004208:0.011409:0.009751:0.010673:0.002891:0.004738
2013 (Accord Healthcare, published online:@0.571285:0.492719:0.915130:0.492719:0.915130:0.478714:0.571285:0.478714:0.008946:0.008946:0.008946:0.008946:0.006910:0.005781:0.012127:0.010536:0.010536:0.010673:0.004514:0.011186:0.006910:0.011152:0.010588:0.011152:0.002891:0.005268:0.009903:0.010536:0.011152:0.004548:0.010588:0.004208:0.006910:0.011135:0.009869:0.011135:0.002891:0.002891:0.006106:0.009903:0.010588:0.011186:0.006910:0.010673:0.009903:0.002891:0.002891:0.009903:0.011118
2012).:@0.571285:0.507019:0.617586:0.507019:0.617586:0.493013:0.571285:0.493013:0.008946:0.008946:0.008946:0.008946:0.005781:0.004738
61.:@0.524248:0.521318:0.547322:0.521318:0.547322:0.507312:0.524248:0.507312:0.009168:0.009168:0.004738
  Accord Healthcare Inc. Letrozole. Vol. 2013:@0.571285:0.521318:0.915176:0.521318:0.915176:0.507312:0.571285:0.507312:0.004738:-0.004738:0.012349:0.010759:0.010759:0.010895:0.004738:0.011409:0.004589:0.011374:0.010810:0.011374:0.003113:0.005490:0.010126:0.010759:0.011374:0.004770:0.010810:0.004589:0.003558:0.010126:0.010759:0.004430:0.004589:0.007594:0.010810:0.005490:0.004770:0.010895:0.006961:0.010895:0.003113:0.010810:0.004430:0.004589:0.009974:0.010895:0.003113:0.004430:0.004591:0.009168:0.009168:0.009168:0.009476
(Accord Healthcare, published online, :@0.571285:0.535617:0.919918:0.535617:0.919918:0.521612:0.571285:0.521612:0.006004:0.012349:0.010759:0.010759:0.010895:0.004738:0.011409:0.017310:0.011374:0.010810:0.011374:0.003113:0.005490:0.010126:0.010759:0.011374:0.004770:0.010810:0.004430:0.017310:0.011357:0.010092:0.011357:0.003113:0.003113:0.006329:0.010126:0.010810:0.011409:0.017310:0.010895:0.010126:0.003113:0.003113:0.010126:0.010810:0.004734:0.004738
2012).:@0.571285:0.549916:0.618698:0.549916:0.618698:0.535911:0.571285:0.535911:0.009168:0.009168:0.009168:0.009168:0.006004:0.004738
62. :@0.524248:0.564216:0.552675:0.564216:0.552675:0.550210:0.524248:0.550210:0.009479:0.009479:0.004731:0.106302
  Pharmacia.  AROMASIN  exemestane:@0.571285:0.564216:0.915149:0.564187:0.915149:0.550181:0.571285:0.550210:0.004738:-0.004738:0.010122:0.010432:0.012880:0.006818:0.017241:0.012880:0.012264:0.004618:0.012880:0.005935:0.004738:0.005015:0.013855:0.011580:0.016061:0.016916:0.013855:0.009715:0.005063:0.012657:0.009334:0.009749:0.012313:0.009407:0.012313:0.017241:0.012313:0.006636:0.005798:0.011682:0.010434:-0.249750
®:@0.787994:0.559192:0.795443:0.559192:0.795443:0.551027:0.787994:0.551027:0.007449
tablets. (patient.cancerconsultants.com, :@0.571271:0.578486:0.919885:0.578486:0.919885:0.564481:0.571271:0.564481:0.005798:0.011682:0.011665:0.003421:0.011118:0.005798:0.006636:0.004738:0.010365:0.006312:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.004738:0.011067:0.011682:0.010434:0.011067:0.011118:0.005022:0.011067:0.011203:0.010434:0.006636:0.010399:0.003421:0.005798:0.011682:0.010434:0.005798:0.006636:0.004738:0.011067:0.011203:0.016044:0.004738:0.004738
published online, 2003).:@0.571271:0.592785:0.764944:0.592785:0.764944:0.578780:0.571271:0.578780:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
63.:@0.524234:0.607085:0.547923:0.607085:0.547923:0.593079:0.524234:0.593079:0.009476:0.009476:0.004738
  Padula AM. GnRH analogues – agonists:@0.571271:0.607085:0.915154:0.607085:0.915154:0.593079:0.571271:0.593079:0.004738:-0.004738:0.010126:0.011682:0.011716:0.010399:0.003421:0.011682:0.008073:0.012657:0.015719:0.004738:0.008073:0.014915:0.010434:0.010382:0.011682:0.008073:0.011682:0.010434:0.011682:0.003421:0.011203:0.011511:0.010399:0.011118:0.006636:0.008073:0.008552:0.008073:0.011682:0.011511:0.011203:0.010434:0.003421:0.006636:0.005798:-0.316633
and  antagonists. :@0.571271:0.621384:0.722781:0.621384:0.722781:0.607378:0.571271:0.607378:0.011682:0.010434:0.011716:0.004738:0.008227:0.011682:0.010434:0.005798:0.011682:0.011511:0.011203:0.010434:0.003421:0.006636:0.005798:0.006636:0.004738:0.004738
Animal  Reproduction :@0.730991:0.621384:0.919900:0.621384:0.919900:0.607378:0.730991:0.607378:0.012657:0.010434:0.003421:0.016044:0.011682:0.003421:0.004738:0.008219:0.010382:0.011118:0.011665:0.005148:0.011203:0.011716:0.010399:0.011067:0.005798:0.003421:0.011203:0.010434:0.004738
Science.:@0.571271:0.635683:0.642750:0.635683:0.642750:0.621678:0.571271:0.621678:0.008518:0.011067:0.003421:0.011118:0.010434:0.011067:0.011118:0.004738
 2005;88:115-126. :@0.642750:0.635683:0.785828:0.635683:0.785828:0.621678:0.642750:0.621678:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738:0.004738
64.:@0.524234:0.649982:0.547513:0.649982:0.547513:0.635977:0.524234:0.635977:0.009271:0.009271:0.004738
  Abbott Laboratories. Lupron depot (leu-:@0.571271:0.649982:0.915154:0.649982:0.915154:0.635977:0.571271:0.635977:0.004738:-0.004738:0.012452:0.011460:0.011460:0.010998:0.005593:0.005593:0.009903:0.007697:0.011477:0.011460:0.010998:0.004943:0.011477:0.005593:0.010998:0.004943:0.003216:0.010913:0.006431:0.004533:0.009903:0.007697:0.010194:0.011460:0.004875:0.010998:0.010228:0.009903:0.011511:0.010913:0.011460:0.010998:0.005593:0.009903:0.006106:0.003216:0.010913:0.010194:0.005679
prorelin acetate) kit. Vol. 2013 (U.S. Nation-:@0.571271:0.664282:0.915185:0.664282:0.915185:0.650276:0.571271:0.650276:0.011460:0.004873:0.010998:0.004871:0.010913:0.003216:0.003216:0.010228:0.004909:0.011477:0.010861:0.010913:0.005593:0.011477:0.005593:0.010913:0.006106:0.004909:0.008381:0.003216:0.005593:0.004533:0.004909:0.010076:0.010998:0.003216:0.004533:0.004909:0.009271:0.009271:0.009271:0.009271:0.004909:0.006106:0.010998:0.004533:0.008313:0.004533:0.004909:0.012452:0.011477:0.005593:0.003216:0.010998:0.010228:0.005679
al  Library  of  Medicine,  published  online, :@0.571271:0.678581:0.919875:0.678581:0.919875:0.664576:0.571271:0.664576:0.011477:0.003216:0.004738:0.004711:0.007697:0.003216:0.011460:0.004943:0.011477:0.004943:0.008963:0.004738:0.004711:0.010998:0.005166:0.004738:0.004711:0.015514:0.010913:0.011511:0.003216:0.010861:0.003216:0.010228:0.010913:0.004533:0.004738:0.004711:0.011460:0.010194:0.011460:0.003216:0.003216:0.006431:0.010228:0.010913:0.011511:0.004738:0.004712:0.010998:0.010228:0.003216:0.003216:0.010228:0.010913:0.004736:0.004738
2012).:@0.571271:0.692880:0.619197:0.692880:0.619197:0.678875:0.571271:0.678875:0.009271:0.009271:0.009271:0.009271:0.006106:0.004738
65. :@0.524234:0.707179:0.552661:0.707179:0.552661:0.693174:0.524234:0.693174:0.009479:0.009479:0.004731:-0.101632
  AstraZeneca.  ZOLADEX  (goserelin ace-:@0.571271:0.707179:0.915154:0.707161:0.915154:0.693156:0.571271:0.693174:0.004738:-0.004738:0.012452:0.006431:0.005593:0.004943:0.011477:0.008005:0.010913:0.010228:0.010913:0.010861:0.011477:0.004533:0.004738:0.007627:0.008005:0.014658:0.007697:0.012452:0.012520:0.008963:0.010417:0.007119:0.012366:0.006106:0.011306:0.010998:0.006431:0.010913:0.004873:0.010913:0.003216:0.003216:0.010228:0.012366:0.011477:0.010861:0.010913:-0.463157
®:@0.765962:0.702167:0.773411:0.702167:0.773411:0.694002:0.765962:0.694002:0.007449
tate implant) 3.6 mg. Vol. 2013 (U.S. Nation-:@0.571273:0.721460:0.915141:0.721460:0.915141:0.707455:0.571273:0.707455:0.005593:0.011477:0.005593:0.010913:0.004054:0.003216:0.015839:0.011460:0.003216:0.011477:0.010228:0.005593:0.006106:0.004054:0.009271:0.004533:0.009271:0.004054:0.015839:0.011306:0.004533:0.004054:0.010076:0.010998:0.003216:0.004533:0.004054:0.009271:0.009271:0.009271:0.009271:0.004054:0.006106:0.010998:0.004533:0.008313:0.004533:0.004054:0.012452:0.011477:0.005593:0.003216:0.010998:0.010228:0.005679
al  Library  of  Medicine,  published  online, :@0.571273:0.735760:0.919877:0.735760:0.919877:0.721754:0.571273:0.721754:0.011477:0.003216:0.004738:0.004711:0.007697:0.003216:0.011460:0.004943:0.011477:0.004943:0.008963:0.004738:0.004711:0.010998:0.005166:0.004738:0.004711:0.015514:0.010913:0.011511:0.003216:0.010861:0.003216:0.010228:0.010913:0.004533:0.004738:0.004711:0.011460:0.010194:0.011460:0.003216:0.003216:0.006431:0.010228:0.010913:0.011511:0.004738:0.004712:0.010998:0.010228:0.003216:0.003216:0.010228:0.010913:0.004736:0.004738
2010).:@0.571273:0.750059:0.619199:0.750059:0.619199:0.736054:0.571273:0.736054:0.009271:0.009271:0.009271:0.009271:0.006106:0.004738
66.:@0.524236:0.764358:0.547925:0.764358:0.547925:0.750353:0.524236:0.750353:0.009476:0.009476:0.004738
  Sanofi-aventis. SUPREFACT . 4 Ed. 56. (Sa-:@0.571273:0.764358:0.915135:0.764351:0.915135:0.750346:0.571273:0.750353:0.004738:-0.004738:0.008518:0.011682:0.010434:0.011203:0.004165:0.004165:0.005679:0.011682:0.009476:0.011118:0.010434:0.005798:0.003421:0.006636:0.004738:0.006209:0.008518:0.011203:0.010126:0.010382:0.009168:0.007261:0.012657:0.013906:0.007286:0.007445:0.004738:0.006209:0.009476:0.006209:0.009168:0.011716:0.004738:0.006209:0.009476:0.009476:0.004738:0.006209:0.006312:0.008518:0.011682:-0.546324
®:@0.787134:0.759356:0.794583:0.759356:0.794583:0.751191:0.787134:0.751191:0.007449
nofi-aventis, published online, 2010).:@0.571286:0.778650:0.868646:0.778650:0.868646:0.764645:0.571286:0.764645:0.010434:0.011203:0.004165:0.004165:0.005679:0.011682:0.009476:0.011118:0.010434:0.005798:0.003421:0.006636:0.004738:0.004738:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
67.:@0.524249:0.792950:0.547330:0.792950:0.547330:0.778944:0.524249:0.778944:0.009171:0.009171:0.004738
  Ferring  GmbH.  GONAPEPTYL   depot  :@0.571286:0.792950:0.919889:0.792946:0.919889:0.778941:0.571286:0.778944:0.004738:-0.004738:0.008603:0.011426:0.005456:0.005456:0.003729:0.010742:0.011819:0.004738:0.012862:0.015223:0.016352:0.011973:0.011990:0.005046:0.004738:0.012869:0.015223:0.015172:0.012965:0.012965:0.010434:0.009476:0.010434:0.007594:0.010434:0.007902:0.007908:0.004738:0.012869:0.012024:0.011426:0.011973:0.011511:0.005795:0.000000:-0.593611
®:@0.837186:0.787951:0.844634:0.787951:0.844634:0.779786:0.837186:0.779786:0.007449
3.75mg. (Published online, 2004).:@0.571282:0.807245:0.841466:0.807245:0.841466:0.793240:0.571282:0.793240:0.009787:0.005044:0.009785:0.009787:0.016352:0.011817:0.004428:0.004738:0.006312:0.010126:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
68.:@0.524245:0.821544:0.547934:0.821544:0.547934:0.807539:0.524245:0.807539:0.009476:0.009476:0.004738
  SCHERING. Androcur 50  mg tablets.:@0.571282:0.821544:0.915158:0.821544:0.915158:0.807539:0.571282:0.807539:0.004738:-0.004738:0.008518:0.013906:0.011682:0.009168:0.010382:0.003866:0.012657:0.014915:0.004738:0.017241:0.012657:0.010434:0.011716:0.005080:0.011203:0.011067:0.010399:0.005148:0.017241:0.009476:0.009476:0.004738:0.012514:0.016044:0.011511:0.017241:0.005798:0.011682:0.011665:0.003421:0.011118:0.005798:0.006636:0.004738
(South African electronic package insert, :@0.571282:0.835844:0.919913:0.835844:0.919913:0.821838:0.571282:0.821838:0.006312:0.008518:0.011203:0.010399:0.005798:0.010434:0.005781:0.012657:0.005371:0.005148:0.003421:0.011067:0.011682:0.010434:0.005781:0.011118:0.003421:0.011118:0.011067:0.005798:0.005073:0.011203:0.010434:0.003421:0.011067:0.005781:0.011665:0.011682:0.011067:0.008586:0.011682:0.011511:0.011118:0.005781:0.003421:0.010434:0.006636:0.011118:0.005148:0.005798:0.004738:0.004738
published online, 1992).:@0.571282:0.850143:0.764954:0.850143:0.764954:0.836138:0.571282:0.836138:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
69.:@0.524245:0.864442:0.547934:0.864442:0.547934:0.850437:0.524245:0.850437:0.009476:0.009476:0.004738
  Watson Laboratories. Flutamide capsule.:@0.571282:0.864442:0.915151:0.864442:0.915151:0.850437:0.571282:0.850437:0.004738:-0.004738:0.015568:0.011682:0.005798:0.006636:0.011203:0.010434:0.007526:0.007902:0.011682:0.011665:0.011203:0.005148:0.011682:0.005798:0.011203:0.005148:0.003421:0.011118:0.006636:0.004738:0.007526:0.008296:0.003421:0.010399:0.005798:0.011682:0.016044:0.003421:0.011716:0.011118:0.007526:0.011067:0.011682:0.011665:0.006636:0.010399:0.003421:0.011118:-0.692867
Vol. 2013  (U.S. National Library of Medi-:@0.571282:0.878741:0.915148:0.878741:0.915148:0.864736:0.571282:0.864736:0.010280:0.011203:0.003421:0.004738:0.008689:0.009476:0.009476:0.009476:0.009476:0.004738:0.003968:0.006312:0.011203:0.004738:0.008518:0.004738:0.008689:0.012657:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.008689:0.007902:0.003421:0.011665:0.005148:0.011682:0.005148:0.009168:0.008689:0.011203:0.005371:0.008689:0.015719:0.011118:0.011716:0.003421:-0.712722
cine, published online, 2011).:@0.571282:0.893041:0.810469:0.893041:0.810469:0.879035:0.571282:0.879035:0.011067:0.003421:0.010434:0.011118:0.004738:0.004738:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
70.:@0.524245:0.907340:0.547934:0.907340:0.547934:0.893335:0.524245:0.893335:0.009476:0.009476:0.004738
  Accord Healthcare Inc. Bicalutamide:@0.571282:0.907340:0.915131:0.907340:0.915131:0.893335:0.571282:0.893335:0.004738:-0.004738:0.012657:0.011067:0.011067:0.011203:0.005029:0.011716:0.016112:0.011682:0.011118:0.011682:0.003421:0.005798:0.010434:0.011067:0.011682:0.005080:0.011118:0.016112:0.003866:0.010434:0.011067:0.004738:0.016112:0.009818:0.003421:0.011067:0.011682:0.003421:0.010399:0.005798:0.011682:0.016044:0.003421:0.011716:0.011118
tablets Vol. 2013 (U.S. National Library of :@0.571282:0.921639:0.919901:0.921639:0.919901:0.907634:0.571282:0.907634:0.005798:0.011682:0.011665:0.003421:0.011118:0.005798:0.006636:0.007286:0.010281:0.011203:0.003421:0.004738:0.007278:0.009476:0.009476:0.009476:0.009476:0.007286:0.006312:0.011203:0.004738:0.008518:0.004738:0.007274:0.012657:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.007286:0.007902:0.003421:0.011665:0.005148:0.011682:0.005148:0.009168:0.007286:0.011203:0.005371:0.004738
Medicine, published online, 2012).:@0.571282:0.935938:0.852443:0.935938:0.852443:0.921933:0.571282:0.921933:0.015719:0.011118:0.011716:0.003421:0.011067:0.003421:0.010434:0.011118:0.004738:0.004738:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
DRUG-CLASS OVERVIEW:@0.084848:0.038601:0.357590:0.038601:0.357590:0.019343:0.084848:0.019343:0.017498:0.014276:0.015405:0.020508:0.007808:0.019121:0.010866:0.017404:0.011712:0.011712:0.006515:0.020438:0.016510:0.012606:0.013356:0.016510:0.005315:0.012606:0.022578